Related references
Note: Only part of the references are listed.Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
Taru Muranen et al.
CANCER CELL (2012)
V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis
Matthias Evert et al.
HEPATOLOGY (2012)
Biliary Infection May Exacerbate Biliary Cystogenesis Through the Induction of VEGF in Cholangiocytes of the Polycystic Kidney (PCK) Rat
Xiang Shan Ren et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma
Chintda Santiskulvong et al.
CLINICAL CANCER RESEARCH (2011)
Cystogenesis in ARPKD results from increased apoptosis in collecting duct epithelial cells of Pkhd1 mutant kidneys
Bo Hu et al.
EXPERIMENTAL CELL RESEARCH (2011)
Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats
Catharina Renken et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)
S6K1 and 4E-BP1 Are Independent Regulated and Control Cellular Growth in Bladder Cancer
Roman Nawroth et al.
PLOS ONE (2011)
mTORC1 signaling: what we still don't know
Xuemin Wang et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2011)
Hypoxia-inducible factor-1α (HIF-1α) and autophagy in polycystic kidney disease (PKD)
Franck Belibi et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2011)
Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells
Patrizia Sini et al.
AUTOPHAGY (2010)
Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia
Francesca Chiarini et al.
CANCER RESEARCH (2010)
The Complexes of Mammalian Target of Rapamycin
Hongyu Zhou et al.
CURRENT PROTEIN & PEPTIDE SCIENCE (2010)
Mammalian Target of Rapamycin Regulates Vascular Endothelial Growth Factor-Dependent Liver Cyst Growth in Polycystin-2-Defective Mice
Carlo Spirli et al.
HEPATOLOGY (2010)
Rapamycin Ameliorates PKD Resulting from Conditional Inactivation of Pkd1
Jonathan M. Shillingford et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease
Iram Zafar et al.
KIDNEY INTERNATIONAL (2010)
Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease
Andreas L. Serra et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease
Gerd Walz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Polycystic Kidney Disease
Peter C. Harris et al.
ANNUAL REVIEW OF MEDICINE (2009)
TORC-Specific Phosphorylation of Mammalian Target of Rapamycin (mTOR): Phospho-Ser2481 Is a Marker for Intact mTOR Signaling Complex 2
Jeremy Copp et al.
CANCER RESEARCH (2009)
Targeting mTOR with rapamycin One dose does not fit all
David A. Foster et al.
CELL CYCLE (2009)
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas
Ta-Jen Liu et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD)
Dagmar-Christiane Fischer et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease
Charles L. Edelstein
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Inhibition of intrahepatic bile duct dilation of the polycystic kidney rat with a novel tyrosine kinase inhibitor gefitinib
Yasunori Sato et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease
JM Shillingford et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Activation of the MEK5/ERK5 cascade is responsible for biliary dysgenesis in a rat model of Caroli's disease
Y Sato et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
Share Paper
